Diakonos Oncology has closed a $20m private placement of Simple Agreements for Future Equity (SAFE) for its Phase II trial of ...

The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel ...

Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced promising results from its ...

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) has achieved a major milestone in the fight against acute myeloid leukemia ...

Expanding the reach of CAR-T therapeutics could unlock promising new treatment possibilities for solid tumour patients.

The presentation will feature the design and objectives of the Phase 1 study, which marks the first clinical application of ...

The autologous immunotherapy consists of the patient’s own T cells engineered to express a chimeric antigen receptor that ...

Title : Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated ...

INB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no ...

InnoCare gets China NMPA approval for Minjuvi in combo with lenalidomide to treat relapsed or refractory diffuse large B-cell lymphoma: Beijing, China Friday, May 23, 2025, 13:00 ...